500124.IN
Dr. Reddy's Laboratories Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic · IN
Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 331.4B | 353.5B | 325.5B | 279.2B | 245.9B |
| Cost of Revenue | 167.4B | 167.0B | 135.1B | 115.6B | 106.5B |
| Gross Profit | 163.9B | 186.5B | 190.4B | 163.6B | 139.3B |
| Operating Expenses | |||||
| R&D Expense | 22.7B | 25.3B | 27.4B | 22.9B | 19.4B |
| SG&A Expense | 112.1B | 112.3B | 93.9B | 77.2B | 68.0B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (499.0M) | — | (2.7B) | (4.2B) | (5.2B) |
| Total Operating Expenses | 134.4B | 137.7B | 118.6B | 95.9B | 82.2B |
| Cost and Expenses | 301.8B | 304.6B | 253.7B | 211.4B | 188.7B |
| Operating Income (EBIT) | 29.6B | 48.9B | 71.8B | 67.7B | 57.1B |
| Non-Operating | |||||
| Interest Income | 7.8B | 8.3B | 2.7B | 2.3B | 1.2B |
| Interest Expense | 4.5B | 3.9B | 2.8B | 1.7B | 1.4B |
| Net Interest Income | 3.2B | 4.3B | (152.0M) | 567.0M | (248.0M) |
| Other Non-Op Income/Expense | 5.7B | 8.8B | 4.9B | 4.1B | 3.2B |
| Non-Operating Income (excl Interest) | (2.9B) | (12.7B) | (7.8B) | (5.9B) | (4.7B) |
| EBT (Pre-Tax Income) | 35.3B | 57.7B | 76.8B | 71.9B | 60.4B |
| Income Tax Expense | 7.6B | 13.0B | 19.5B | 16.2B | 15.3B |
| Bottom Line | |||||
| Net Income | 28.0B | 45.1B | 56.5B | 55.7B | 45.1B |
| Earnings from Cont. Ops | 27.6B | 44.7B | 57.2B | 55.7B | 45.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 28.0B | 45.1B | 56.5B | 55.7B | 45.1B |
| Per Share | |||||
| Basic EPS | $34.01 | $53.92 | $67.85 | $66.80 | $54.29 |
| Diluted EPS | $34.00 | $53.92 | $67.77 | $66.80 | $54.17 |
| Revenue Per Share | $397.66 | $424.64 | $390.65 | $334.91 | $296.18 |
| Shares | |||||
| Basic Shares Outstanding | 833.3M | 832.4M | 833.3M | 833.5M | 830.2M |
| Diluted Shares Outstanding | 833.3M | 833.3M | 834.3M | 833.5M | 831.9M |
| Profitability Metrics | |||||
| EBITDA | 54.0B | 83.3B | 96.7B | 88.4B | 74.4B |
| D&A | 21.5B | 21.7B | 17.1B | 14.8B | 12.6B |
| EBIT | 32.5B | 61.6B | 79.6B | 73.6B | 61.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026